These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25773959)

  • 1. Complex interplay between the length and composition of the huntingtin-derived peptides modulates the intracellular behavior of the N-terminal fragments of mutant huntingtin.
    Milewski M; Gawliński P; Bąk D; Matysiak A; Bal J
    Eur J Cell Biol; 2015 May; 94(5):179-89. PubMed ID: 25773959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cellular model that recapitulates major pathogenic steps of Huntington's disease.
    Lunkes A; Mandel JL
    Hum Mol Genet; 1998 Sep; 7(9):1355-61. PubMed ID: 9700187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture.
    Cooper JK; Schilling G; Peters MF; Herring WJ; Sharp AH; Kaminsky Z; Masone J; Khan FA; Delanoy M; Borchelt DR; Dawson VL; Dawson TM; Ross CA
    Hum Mol Genet; 1998 May; 7(5):783-90. PubMed ID: 9536081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification of neuronal inclusions of patients with Huntington's disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers.
    Hoffner G; Island ML; Djian P
    J Neurochem; 2005 Oct; 95(1):125-36. PubMed ID: 16181417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Huntingtin fragments that aggregate go their separate ways.
    DiFiglia M
    Mol Cell; 2002 Aug; 10(2):224-5. PubMed ID: 12191468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease.
    Hackam AS; Singaraja R; Zhang T; Gan L; Hayden MR
    Hum Mol Genet; 1999 Jan; 8(1):25-33. PubMed ID: 9887328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment.
    Muchowski PJ; Ning K; D'Souza-Schorey C; Fields S
    Proc Natl Acad Sci U S A; 2002 Jan; 99(2):727-32. PubMed ID: 11792857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sigma-1 receptor is involved in degradation of intranuclear inclusions in a cellular model of Huntington's disease.
    Miki Y; Tanji K; Mori F; Wakabayashi K
    Neurobiol Dis; 2015 Feb; 74():25-31. PubMed ID: 25449906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions.
    Lunkes A; Lindenberg KS; Ben-Haïem L; Weber C; Devys D; Landwehrmeyer GB; Mandel JL; Trottier Y
    Mol Cell; 2002 Aug; 10(2):259-69. PubMed ID: 12191472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
    Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
    J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment.
    Persichetti F; Trettel F; Huang CC; Fraefel C; Timmers HT; Gusella JF; MacDonald ME
    Neurobiol Dis; 1999 Oct; 6(5):364-75. PubMed ID: 10527804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-Terminal Fragments of Huntingtin Longer than Residue 170 form Visible Aggregates Independently to Polyglutamine Expansion.
    Chen MZ; Mok SA; Ormsby AR; Muchowski PJ; Hatters DM
    J Huntingtons Dis; 2017; 6(1):79-91. PubMed ID: 28339398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats.
    Li SH; Li XJ
    Hum Mol Genet; 1998 May; 7(5):777-82. PubMed ID: 9536080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental mutagenesis of huntingtin to map cleavage sites: different outcomes in cell and mouse models.
    Tebbenkamp AT; Xu G; Siemienski ZB; Janus C; Fromholt SE; Brown HH; Swing D; Tessarollo L; Borchelt DR
    J Huntingtons Dis; 2014; 3(1):73-86. PubMed ID: 25062766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The composition of the polyglutamine-containing proteins influences their co-aggregation properties.
    Bak D; Milewski M
    Cell Biol Int; 2010 Sep; 34(9):933-42. PubMed ID: 20515443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein aggregation in Huntington's disease.
    Hoffner G; Djian P
    Biochimie; 2002 Apr; 84(4):273-8. PubMed ID: 12106904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Huntingtin processing in pathogenesis of Huntington disease.
    Qin ZH; Gu ZL
    Acta Pharmacol Sin; 2004 Oct; 25(10):1243-9. PubMed ID: 15456523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death.
    Arrasate M; Mitra S; Schweitzer ES; Segal MR; Finkbeiner S
    Nature; 2004 Oct; 431(7010):805-10. PubMed ID: 15483602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
    Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein.
    Sieradzan KA; Mechan AO; Jones L; Wanker EE; Nukina N; Mann DM
    Exp Neurol; 1999 Mar; 156(1):92-9. PubMed ID: 10192780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.